Arrhythmia Alliance Launches Healthcare Pioneers Report to Showcase Best Practice in Supraventricular Tachycardia

The report will be used to inspire centers across the globe to improve care and quality of life for people with supraventricular tachycardia

The non-profit organization Arrhythmia Alliance has launched the Arrhythmia Alliance Healthcare Pioneers Report — Showcasing Best Practice in SVT to provide examples of good care to inspire Centers across the globe to improve outcomes and quality of life of people with the arrhythmia (heart rhythm disorder) supraventricular tachycardia (SVT). The report follows the established Healthcare Pioneer Reports: AF Association Healthcare Pioneers Report — Showcasing Best Practice in AF and STARS Healthcare Pioneers Report — Showcasing Best Practice in Syncope. ­Published by Arrhythmia Alliance’s sister non-profit organizations, AF Association and STARS respectively, these reports outline innovative approaches to managing atrial fibrillation (AF) and syncope (fainting).

SVT is a rapid increase in resting heart rate (above 100 beats per minute) that originates in the atria (the upper chambers of the heart). In the USA, it has an approximate prevalence of 140 per 100,000 and an incidence of 73 per 100,000.1 The diagnosis of SVT can be challenging because the condition is episodic in nature (ie, does not occur all the time) and, therefore, is difficult to identify unless an electrocardiogram (EKG) can record an episode at the time it occurs. Another challenge is that despite treatment (eg, medication such as beta-blockers), some people with SVT continue to have symptoms. Additionally, some people discontinue taking medication because they cannot tolerate the side effects.

Therefore, the aim of Arrhythmia Alliance Healthcare Pioneers Report — Showcasing Best Practice in SVT is to explore innovative approaches to diagnosing and treating SVT. For example, in the 2021 report, Dr. Shouvik Haldar (Royal Brompton & Harefield Hospital, London, UK) reviews the use of personal EKG devices to diagnose SVT while COVID-19 restrictions are in place and Dr. Benjamin A. Steinberg (Clinical Cardiac Electrophysiology, University of Utah, Salt Lake City, USA) looks at the home-based use of the investigational drug Etripamil to reduce SVT episodes.

Professor Hugh Calkins (Johns Hopkins Medical Institutions, Baltimore, MD, USA), Medical Director & Board Member, Arrhythmia Alliance, comments: “The case studies in this report examine the current challenges in diagnosing and managing people with SVT and provide potential solutions to these challenges. However, the aim of the SVT Pioneers report is not just to ‘Showcase Best Practice” but also to encourage centers across the globe to consider what innovative approaches they could adopt to improve care and quality of life for people with SVT. 

Ultimately, with the report, we want to inspire other Centers to become “SVT Pioneers” and “Centers of Excellence”. 

The report will be published on the dedicated SVT Pioneers website (, which also has an online database of SVT “Centers of Excellence”. The aim of the Centers of Excellence database is to enable people with SVT to locate Centers of Excellence within their area and to help non-SVT healthcare professionals, such as general practitioners, identify Centers that they can refer patients to — with both patients and healthcare professionals safe in the knowledge that the Centers have been vetted, by Arrhythmia Alliance, as institutions that provide excellent and reliable care.

Mrs. Trudie Lobban, Founder and CEO of Arrhythmia Alliance, says: “At Arrhythmia Alliance, we have always advocated the importance of ‘turning the patient back into a person’. With this new report, we hope to encourage Centers across the globe to seek new ways to improve the care and quality of life with people with SVT. We believe that by working together, healthcare professionals and people with SVT can overcome the current challenges of this condition.”

She continues: “With our new Centers of Excellence database, we are providing a resource that helps people with SVT find and receive the care that they need. SVT is rarely life-threatening, but it can be life-changing. Our goal, with the report and the Centers of Excellence database, is to ensure that people with SVT can go about their daily lives without having to be concerned about their condition.”

Arrhythmia Alliance (A-A) provides support, information, education, and awareness to all those affected by or involved in the care of cardiac arrhythmias.

Arrhythmia Alliance Healthcare Pioneers Report — Showcasing Best Practice in SVT 2021 can be downloaded from here:

Submissions for Arrhythmia Alliance Healthcare Pioneers Report — Showcasing Best Practice in SVT 2022 will open June 7th, 2021, marking the start of Arrhythmia Alliance World Heart Rhythm Week 2021 (WHRW; 7–13 June). For more information about WHRW, visit:


  1. Go AS, Hlatky MA, Liu TI, et al. Contemporary burden and correlates of symptomatic paroxysmal supraventricular tachycardia. J Am Heart Assoc. 2018;7:e008759.